Mika Nishimura

MobileODT Ltd. develops optical diagnostic devices and software services focused on early cancer detection. It uses mobile phones to detect cancer and also develops point-of-care diagnostic solutions for the global market. The firm’s product EVA System, functions on its own as an enhanced visual assessment screening or alongside any cervical cancer treatment. The company was founded by Ariel Beery and David Levitz in October 2012 and is headquartered in Tel Aviv, Israel.

nVision Medical Corp. operates as a venture-backed medical device company. It develops a technology that can be used in the office of the gynecologist to diagnose the cause of infertility as well as ovarian cancer. The company was founded by Surbhi Sarna in January 2012 and is headquartered in San Francisco, CA.

Auxogyn, Inc. provides novel scientific and development biotechnology services. It is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The firm's first product, the Eeva test, is designed to provide quantitative information regarding embryo development to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. The company was founded by Renee A. Reijo Pera, Barry Behr, Thomas Baer, Connie Wong, Lissa A. Goldenstein and Kevin Loewke in 2008 and is headquartered in Menlo Park, CA.

ev3, Inc. is a provider for specialists treating a range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering a portfolio of treatment options, including interventional technologies used such as plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, embolization coils, liquid embolics, occlusion balloons and procedural support.